Clinical Trial: Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody, in Participants With Relapsed or Refractory Multiple Myeloma

This trial is evaluating dose escalation and expansion of a new Janssen drug called JNJ-64007957. JNJ-64007957 is a bi-specific antibody, a new kind of drug which has two targets. One of its targets is BCMA, a protein found on myeloma cells, and the other is CD3, which is found on our T cells. The drug joins your T cell to the myeloma target for directed killing.

This approach can help our immune system identify and fight myeloma more efficiently. To learn more about Bi-specific Antibodies, check out our previous article here.

This Phase 1 trial will include 60 participants from several facilities and will have two parts: dose escalation and dose expansion.

Patients will receive JNJ-64007957 intravenously, and will be monitored for dose limiting toxicities, adverse events, and serum concentrations of JNJ-64007957.

Participants must have relapsed/refractory myeloma, and previous lines of therapy must include both a proteasome inhibitor and an immunomodulatory agent.

This trial is open and accepting patients at several locations throughout the US. Click the link below to learn more about this study and see if you are eligible. You can also call SparkCures with any questions at (888) 828-2206.

Dose Escalation Study of JNJ-64007957, a Humanized BCMA CD3 DuoBody® Antibody

• Open-Label: Patients and their doctors will know both the treatment and the dose that they will be receiving.
• Single-Arm: All patients enrolled in this trial will receive the same experimental treatment.
• Multi-center: This trial will be available to patients at multiple cancer centers around the country.
• Dose Escalation: The amount of the study drug is periodically increased to determine the maximum tolerated dose (MTD) to be used in future trials.